Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Severe Insulin Resistance Clear all
Completed Phase 4 Interventional Results available

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Resistance
Interventions
U-500 Insulin delivered by Omnipod (disposable insulin pump)
Drug
Lead sponsor
Mountain Diabetes and Endocrine Center
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Jul 23, 2026, 7:08 PM EDT
Terminated No phase listed Observational

Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features

NCT01310140
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder w/ Psychotic Features, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of Strawberries and Disease Risk

NCT01199848
View directory record Official record
Conditions
Nutritional and Metabolic Diseases, Inflammation, Physiological Responses
Interventions
Placebo, 10G, 20G, 40G, Placebonofiber
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Diet and Depression

NCT06252701
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Weight Gain, Obesity, Metabolic Syndrome
Interventions
Reduction of Ultra-processed foods
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional

Leptin to Treat Severe Insulin Resistance - Pilot Study

NCT00027456
View directory record Official record
Conditions
Syndrome
Interventions
Leptin A-100
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 7:08 PM EDT
Not yet recruiting Not applicable Interventional

Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling

NCT06748950
View directory record Official record
Conditions
Schizophrenia, Schizophrenia and Related Disorders, Bipolar Disorder, Bipolar and Related Disorders, Major Depressive Disorder, Major Depression Severe, Ketogenic Dieting, Ketosis, Metabolic Disease, Metabolic Syndrome
Interventions
LCHF Ketogenic Diet, Diet-as-Usual (DAU)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed No phase listed Observational

Insulin Resistance in Severely Obese Patients

NCT00275223
View directory record Official record
Conditions
Obesity, Insulin Resistance, Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Versus Insulin in Pregnant Women With Type 2 Diabetes

NCT00678080
View directory record Official record
Conditions
Pregnancy Complications
Interventions
Metformin, Insulin (NPH and Regular)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Brownsville, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2018 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Jul 23, 2026, 7:08 PM EDT
Recruiting Phase 2 Interventional

Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

NCT05470504
View directory record Official record
Conditions
Insulin Receptor Mutation, Partial Lipodystrophy
Interventions
Pegvisomant
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 4 Interventional Results available

Pioglitazone in Patients With Mood Disorders

NCT01559857
View directory record Official record
Conditions
Major Depressive Disorder, Insulin Resistance
Interventions
Pioglitazone, Sugar Pill
Drug
Lead sponsor
Stanford University
Other
Eligibility
20 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 1Phase 2 Interventional

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

NCT02324309
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
BIOD-531, Humalog Mix 75/25, Humulin R U-500
Drug
Lead sponsor
Biodel
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Jul 23, 2026, 7:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Individual Differences in Diabetes Risk: Role of Slow WaveSleep

NCT00989378
View directory record Official record
Conditions
Sleep, Diabetes
Interventions
baseline study
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 20 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

NCT04776629
View directory record Official record
Conditions
Psoriasis, Inflammation, Coronary Artery Disease, Cardiometabolic Syndrome
Interventions
Orticumab, Placebo
Drug
Lead sponsor
Abcentra
Industry
Eligibility
30 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Scottsdale, Arizona • Santa Monica, California • Tustin, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

NCT00004419
View directory record Official record
Conditions
Insulin Resistance, Hyperglycemia
Interventions
insulin-like growth factor I
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
14 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

NCT06548100
View directory record Official record
Conditions
Generalized Lipodystrophy
Interventions
mibavademab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 23, 2026, 7:08 PM EDT
Completed No phase listed Observational

Peds Metabolic Syndrome in Psoriasis

NCT00930592
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome
Interventions
Not listed
Lead sponsor
Tufts Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 7:08 PM EDT
Not listed Not applicable Interventional

The S.L.I.M.M.S. Procedure for Severe Clinical Obesity

NCT04592601
View directory record Official record
Conditions
Morbid Obesity, Metabolic Syndrome, Type2 Diabetes, Insulin Resistance
Interventions
S.L.I.M.M.S. Procedure
Procedure
Lead sponsor
The N.E.W. Program
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Evaluating the Tolerability and Effects of Berberine on Major Metabolic Biomarkers: A Pilot Study

NCT03976336
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Berberine, Identical Placebo
Dietary Supplement · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 23, 2026, 7:08 PM EDT
Completed Not applicable Interventional

Insulin on Post Burn Hypermetabolism

NCT00137254
View directory record Official record
Conditions
Burns
Interventions
Insulin, Stable Isotopes, Indocyanine Green
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 72 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Jul 23, 2026, 7:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 7:08 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance

NCT00085982
View directory record Official record
Conditions
Severe Insulin Resistance
Interventions
Metreleptin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 23, 2026, 7:08 PM EDT